Phase II trial of anastrozole in women with asymptomatic müllerian cancer (Q38449608)

2

1 reference

3 September 2017

Nora K Horick

4

1 reference

3 September 2017

Annekathryn Goodman

5

1 reference

3 September 2017

Linda R Duska

6

1 reference

3 September 2017

Richard Penson

7

1 reference

3 September 2017

Susana Campos

8

1 reference

3 September 2017

Maria Roche

9

1 reference

3 September 2017

Michael V Seiden

10

1 reference

3 September 2017

language of work or name

English

0 references

publication date

1 December 2003

1 reference

3 September 2017

1 reference

3 September 2017

91

1 reference

3 September 2017

596-602

1 reference

3 September 2017

3

1 reference

3 September 2017

Cancer statistics, 2001

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.08.021

Ovarian cancer: latest gains establish new battle fronts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.08.021

Phase II trial of medroxyprogesterone acetate in advanced ovarian cancer: an EORTC Gynecological Cancer Cooperative Group Study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.08.021

A randomized, open, parallel-group trial to compare the endocrine effects of oral anastrozole (Arimidex) with intramuscular formestane in postmenopausal women with advanced breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.08.021

New aromatase inhibitors for the treatment of advanced breast cancer in postmenopausal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.08.021

Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.08.021

Aromatase inhibitors in the treatment and prevention of breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.08.021

Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.08.021

Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.08.021

Immunohistochemical studies of steroidogenic enzymes (aromatase, 17 alpha-hydroxylase and cholesterol side-chain cleavage cytochromes P-450) in sex cord-stromal tumors of the ovary

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.08.021

Steroid receptors and ovarian tumors: variation within primary tumors and between primary tumors and metastases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.08.021

Phase II study of high-dose megestrol acetate in patients with advanced ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.08.021

Phase II study of high-dose megestrol acetate in platinum-refractory epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.08.021

Hormonal palliation of chemoresistant ovarian cancer: three consecutive phase II trials of the Mid-Atlantic Oncology Program

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.08.021

Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.08.021

Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group Ancillary Report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.08.021

Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.08.021